Pay in 4 interest-free payments of $5.36 Learn more
Ships within 48 hours · Estimated delivery Aug 28 - Sep 2
Product sold online is unregulated, with purity and dosing unverifiable
First, Drs
For patent valuation: a biologic patent portfolio that effectively delays interchangeability designation through litigation, licensing agreements with entry date conditions, or product hopping to a formulation the biosimilar doesnt reference materially extends the revenue tail beyond what the patent expiration dates alone would suggest
The lower rate of treatment discontinuation in the trials may potentially be explained by patient monitoring and encouragement to adhere to the protocol, and/or selective inclusion of patients who are more likely to adhere to treatment
US$ 26.48
US$ 23.57
US$ 25.72
US$ 23.76
US$ 22.73
US$ 26.53
US$ 24.63
US$ 26.14
US$ 20.32
US$ 24.32
